Clinical Trials Sponsored by Neuroglee Therapeutics

Total 6252 results

Neuroglee Therapeutics

Completed

Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment

Mild Cognitive Impairment

Singapore
NeuroGlove LLC

Not yet recruiting

NeuroGlove fMRI Study

Stroke | Ischemic Stroke, Acute
Neurogene Inc.

Recruiting

Gene Therapy Study for Children With CLN5 Batten Disease (CLN5-200)

Neuronal Ceroid Lipofuscinosis CLN5

United States, United Kingdom
NeuroGlove LLC

Recruiting

NeuroGlove Anxiety and Depression Study

Depression | Anxiety | Anxiety Depression | Depression, Anxiety

United States
Neurogene Inc.

Recruiting

A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)

Ceroid Lipofuscinosis, Neuronal 5

United States
Neurogene Inc.

Terminated

A Natural History Study of Aspartylglucosaminuria (AGU)

Lysosomal Storage Diseases | Aspartylglucosaminuria | Aspartylglucosamidase (AGA) Deficiency

United States
Neurogene Inc.

Recruiting

A Novel, Regulated Gene Therapy (NGN-401) Study for Female Children With Rett Syndrome

Rett Syndrome

United States
NeuroGlove LLC

Active, not recruiting

NeuroGlove PTSD Study

PTSD | Post Traumatic Stress Disorder

United States
Neurogene Inc.

Terminated

A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) (CMT4J)

Charcot-Marie-Tooth Disease | Hereditary Motor and Sensory Neuropathy IV

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

Early Parkinson Disease

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

Primary Insomnia

United States
Neurogen Brain and Spine Institute

Withdrawn

Cell Therapy in Limb Girdle Muscular Dystrophy

Limb Girdle Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

Cerebrovascular Accident

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury

Spinal Cord Injury

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Muscular Dystrophy

Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Mental Retardation

Mental Retardation

India
Neurogen Brain and Spine Institute

Withdrawn

Cell Therapy as Treatment for Cerebral Palsy

Cerebral Palsy

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Spinal Cord Injury

Spinal Cord Injury

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Limb Girdle Muscular Dystrophy

Limb Girdle Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Autism Spectrum Disorders

Autism Spectrum Disorders

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy for Cerebral Palsy

Cerebral Palsy

India
Neurogen Brain and Spine Institute

Withdrawn

Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Traumatic Brain Injury

Traumatic Brain Injury

India
Neurogen Brain and Spine Institute

Withdrawn

Autologous Stem Cell Therapy in Stroke

Stroke

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Incurable Neurological Disorders

Neurological; Disorder, Nervous System

India
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
CRISPR Therapeutics AG
ViaCyte

Recruiting

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Melinta Therapeutics, LLC

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Gram Positive Bacterial Infections

United States
TenNor Therapeutics Limited

Completed

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI)

Gram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial Infections

United States
CRISPR Therapeutics AG
ViaCyte

Completed

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States

Clinical Trials Sponsored by Neuroglee Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations